Persistence rate with medical treatment in patients with idiopathic or neurogenic overactive bladder

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13129226

Enrollment

123

Registered

2017-03-17

Start date

2009-06-01

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder Urological and Genital Diseases Other specified disorders of bladder

Interventions

After giving informed consent, patients older than 18 years and newly prescribed solifenacin because of complaints of idiopathic or neurogenic OAB, were included. Patients who had used anticholinergic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years 2. Idiopathic or neurogenic overactive bladder 3. Newly prescribed solifenacin

Exclusion criteria

Exclusion criteria: 1. Patients not on solifenacin 2. Patients who had used anticholinergic drugs less than 7 days before they started solifenacin

Design outcomes

Primary

Measure	Time frame
Persistence of usage, measured by telephone surveys at 1, 3, 6 and 12 months	—

Secondary

Measure	Time frame
Reasons for stopping medication, measured by telephone surveys at 1, 3, 6 and 12 months	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026